

## SYSTEMATIC REVIEW

## Systematic Review of the Efficacy of Treatment for Median Arcuate Ligament Syndrome

Flores M. Metz <sup>a,b,c,\*</sup>, Juliëtte T.M. Blauw <sup>a,c</sup>, Marjolein Brusse-Keizer <sup>c,d,e</sup>, Jeroen J. Kolkman <sup>c,f</sup>, Marco J. Bruno <sup>g</sup>, Robert H. Geelkerken <sup>a,b,c</sup>, on behalf of the Dutch Mesenteric Ischaemia Study Group

<sup>a</sup> Department of Vascular Surgery, Medisch Spectrum Twente, Enschede, the Netherlands

<sup>b</sup> Multi-Modality Medical Imaging Group, TechMed Centre, University of Twente, Enschede, the Netherlands

<sup>c</sup> Dutch Expert Centre for Gastrointestinal Ischaemia, Enschede, the Netherlands

<sup>d</sup> Medical School Twente, Medisch Spectrum Twente, Enschede, the Netherlands

<sup>e</sup> Health Technology and Services Research, University of Twente, Enschede, the Netherlands

<sup>f</sup> Department of Gastroenterology, Medisch Spectrum Twente, Enschede, the Netherlands

<sup>g</sup> Department of Gastroenterology and Hepatology, Erasmus MC University Medical Centre, Rotterdam, the Netherlands

### WHAT THIS PAPER ADDS

This systematic review suggests sustainable symptom relief above 70% after treatment for median arcuate ligament syndrome (MALS) in the majority of adult and paediatric studies, but the risk of bias is high and a formal meta-analysis could not be performed. This outcome supports guideline committees, acknowledging that MALS exists as a disease entity. However, studies of sufficient scientific quality are lacking to recommend specific treatments. To improve care for patients with MALS the next steps would be to deal with reporting standards, outcome definitions, and consensus descriptions of the intervention(s), after which an appropriate randomised controlled trial could be performed.

**Objective:** Since the first description of the median arcuate ligament syndrome (MALS), the existence for the syndrome and the efficacy of treatment for it have been questioned.

**Methods:** A systematic review conforming to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement was conducted, with a broader view on treatment for MALS including any kind of coeliac artery release, coeliac plexus resection, and coeliac plexus blockage, irrespective of age. Online databases were used to identify papers published between 1963 and July 2021. The inclusion criteria were abdominal symptoms, proof of MALS on imaging, and articles reporting at least three patients. Primary outcomes were symptom relief and quality of life (QoL).

**Results:** Thirty-eight studies describing 880 adult patients and six studies describing 195 paediatric patients were included. The majority of the adult studies reported symptom relief of more than 70% from three to 228 months after treatment. Two adult studies showed an improved QoL after treatment. Half of the paediatric studies reported symptom relief of more than 70% from six to 62 months after laparoscopic coeliac artery release, and four studies reported an improved QoL. Thirty-five (92%) adult studies and five (83%) paediatric studies scored a high or unclear risk of bias for the majority of the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) items. The meaning of coeliac plexus resection or blockage could not be substantiated.

**Conclusion:** This systematic review suggests a sustainable symptom relief of more than 70% after treatment for MALS in the majority of adult and paediatric studies; however, owing to the heterogeneity of the inclusion criteria and outcome parameters, the risk of bias was high and a formal meta-analysis could not be performed. To improve care for patients with MALS the next steps would be to deal with reporting standards, outcome definitions, and consensus descriptions of the intervention(s), after which an appropriate randomised controlled trial should be performed.

**Keywords:** Coeliac Artery Compression Syndrome, Coeliac Artery Release, Dunbar Syndrome, Median Arcuate Ligament Syndrome, Plexus Blockage, Systematic Review

Article history: Received 27 February 2022, Accepted 28 August 2022, Available online 6 September 2022

© 2022 The Authors. Published by Elsevier B.V. on behalf of European Society for Vascular Surgery. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

\* Corresponding author. Department of Vascular Surgery, Medisch Spectrum Twente PO Box 50.000, Koningsplein 1, 7500 KA Enschede, the Netherlands.  
E-mail address: [flores.metz@mst.nl](mailto:flores.metz@mst.nl) (Flores M. Metz).

1078-5884/© 2022 The Authors. Published by Elsevier B.V. on behalf of European Society for Vascular Surgery. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).  
<https://doi.org/10.1016/j.ejvs.2022.08.033>

## INTRODUCTION

The existence of median arcuate ligament syndrome (MALS) as a distinct entity caused by an increase of mucosal ischaemia,<sup>1</sup> and the efficacy of its treatment, has been questioned for a long time with respected physicians drawing different conclusions from the existing data.<sup>2–4</sup> The combination of a varying patient presentation, non-specific abdominal symptoms, and lack of validated, non-invasive mesenteric perfusion tests makes the diagnosis of MALS challenging to establish. Current international guidelines recommend that the diagnosis should be based on symptoms fitting chronic mesenteric ischaemia (CMI) and imaging studies showing compression of the coeliac artery (CA) by the median arcuate ligament (MAL) evaluated by an experienced multidisciplinary team, consisting of dedicated gastroenterologists, vascular surgeons, and radiologists.<sup>2,3</sup>

Ninety-six per cent of the experts on panel of the European CMI guidelines recommended that patients with MALS might be considered for surgical CA release, but consensus could not be reached on the first choice of treatment strategy and, consequently, clear recommendations are lacking.<sup>3</sup> Some publications have reported that local coeliac plexus blockage could be an alternative effective treatment for MALS,<sup>5,6</sup> but this has not been described as a treatment option in two comprehensive sets of guidelines.<sup>2,3</sup>

In 2012, Jimenez *et al.* published a systematic review of 20 retrospective studies reporting immediate symptom improvement in 85% of 400 patients with MALS after laparoscopic and open CA release, with a late recurrence in 19 patients in the open group (6.8%) and seven patients in the laparoscopic group (5.7%).<sup>7</sup> Limitations of the review by Jimenez *et al.* are that the evidence was based on mostly small individual series, the age of the patients was not reported, and the follow up period in the laparoscopic treatment group was short. After Jimenez *et al.*,<sup>7</sup> in 2020 Goodall *et al.* described more recent literature in a narrative review, but the review presented did not conform to the methodology of a systematic review. There has been no systematic review published on MALS treatment and outcomes in the past decade.<sup>8</sup> Furthermore, the most obvious outcome measure by today's standard, the impact of MALS on the

quality of life (QoL) of patients before and after treatment, was not reported in the previous reviews.

The aim of the current systematic review was to summarise systematically the available literature on treatment, including open, laparoscopic, and robotic assisted CA release techniques, coeliac plexus blockage, and outcomes, including individual and societal gains in QoL, for adult and paediatric patients with MALS.

## MATERIALS AND METHODS

### Search strategy

The study protocol for this systematic review was registered with the international prospective register of systematic reviews (PROSPERO) and conformed to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (PROSPERO CRD42021258592).<sup>9</sup> The literature search was performed according to the standards set out in the PRISMA statement.<sup>9</sup> Firstly, systematic searches in PubMed, the Cochrane Library, and Embase were performed to identify the relevant literature (details of the search strategy are shown in the Supplementary Literature Search). Secondly, all references cited in the existing reviews on MALS were hand searched for additional citations.


### Study selection

The search focused on studies describing the outcomes MALS treatment published between its first description in 1963 up until 16 July 2021. Duplicates were removed. Patient cohorts could be included irrespective of age at presentation and treatment. The most important inclusion criteria were the presence of abdominal symptoms; proof of external compression of the CA on imaging; surgical treatment for MALS or plexus blockage; and at least three patients included in the study (Table 1). Grey literature was not included in this review.

Articles were independently selected by two authors (F.M.M. and J.T.M.B.), who were blinded to each other. The first selection was done by screening the titles and abstracts according to the pre-defined inclusion and exclusion criteria. Next, full text articles were read for inclusion in the

**Table 1. Inclusion and exclusion criteria of a systemic review of the treatment for median arcuate ligament syndrome (MALS)**

| Inclusion  | Exclusion  |
|--|--|
| Between 1963 up to 16 July 2021<br>English language  | Other than inclusion languages<br>Comments, letter to editor, or other forms of own opinions without scientific substantiation |
| Randomised controlled trial, cohort, retrospective and prospective studies   | Fewer than three patients included   |
| External compression of the coeliac artery by the median arcuate ligament syndrome (MALS) on computed tomography angiography, magnetic resonance angiography, duplex ultrasound, or diagnostic angiography | No abstract or full text available   |
| Abdominal symptoms   | No treatment performed   |
| Surgical treatment for MALS or plexus block  | Surgery for MALS combined with other surgery   |
| Outcomes of treatment reported   |  |



final selection; consensus needed to be reached for an article to be included. In the case of disagreement, a third screener (R.H.G.) was involved to achieve consensus. Full texts were accessed via PubMed and through national and international library requests. If full texts could not be retrieved, the article was excluded.

### Outcome parameters

The following outcomes were described: study design and diagnostic criteria (imaging study, abdominal symptoms, and multidisciplinary diagnosis); Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) appraisal of the included studies; and patient demographics (age, sex, duration of symptoms, body mass index, treatment, and additional procedures). The primary outcomes were symptom relief and QoL. The secondary outcomes were clinical outcomes (use of narcotics, death, complications, post-operative adjunctive procedures, psychiatric diagnosis, loss of productivity, and disability adjusted life years) and anatomical data (patency after treatment and duplex outcomes).

Continuous variables were displayed as means (with 95% confidence intervals [CIs]) or median (with interquartile range) for parametric and non-parametric data, respectively. Categorical variables were displayed as numbers (percentages). Patients aged less than 18 years and adults

aged 18 years and older were analysed as separate cohorts (paediatric and adult, respectively).

All results were described in a narrative style. The primary and secondary outcomes described were divided according to the adult and paediatric literature. Data on symptom relief were presented as a forest plot to provide insight into the data at a study level.

### Assessment of methodological quality

The risk of bias and applicability of the articles was evaluated by the QUADAS-2 tool.<sup>10</sup> The answers to the signalling questions and the applicability to the research were discussed after which the final appraisal was defined (F.M.M., J.T.M.B., and R.H.G.).

### Data extraction

Data on study design, patient demographics, and outcome parameters were extracted from the included articles. Data on children (< 18 years old) were reported separately.

## RESULTS

### Search outcome and selection

A total of 611 papers were identified of which 58 including adults and 13 including paediatric patients (< 18 years old)

**Table 2. Study design and diagnostic criteria for 880 adult patients as reported in 38 studies for the treatment of median arcuate ligament syndrome**

| Reference                        | Study design  | Mean follow up – mo* | Lost to follow up – n | Patients – n | Imaging study             | Abdominal symptoms >3 mo* | Multidisciplinary diagnosis |
|----------------------------------|---------------|----------------------|-----------------------|--------------|---------------------------|---------------------------|-----------------------------|
| Baccari (2009) <sup>42</sup>     | Retrospective | 28                   |                       | 16           | DUS and CTA or MRA        | Yes                       | No                          |
| Barbon (2021) <sup>5</sup>       | Prospective   |                      |                       | 22           | CTA                       | Yes                       | No                          |
| Berard (2012) <sup>33</sup>      | Retrospective | 35                   |                       | 11           | CTA                       | Yes, three mo unspecified | No                          |
| Berge (2020) <sup>13</sup>       | Prospective   | Median 18            |                       | 12           | CTA                       | Yes, three mo unspecified | Yes                         |
| Chaum (2021) <sup>28</sup>       | Retrospective |                      |                       | 4            | DUS and CTA and MRA       | Yes, three mo unspecified | No                          |
| Cienfuegos (2018) <sup>12</sup>  | Retrospective | Median 117 (100–160) |                       | 11           | CTA or MRA or DSA         | Yes                       | Yes                         |
| Coelho (2020) <sup>43</sup>      | Prospective   | 3                    |                       | 6            | DUS or MRA                | Yes                       | No                          |
| Columbo (2015) <sup>23</sup>     | Retrospective | Median 7             |                       | 21           | DUS or CTA or DSA         | Yes, three mo unspecified | No                          |
| De'Ath (2018) <sup>31</sup>      | Prospective   | Median 109 (78–114)  |                       | 6            | DUS and CTA or MRA or DSA | Yes, three mo unspecified | No                          |
| Do (2013) <sup>24</sup>          | Retrospective |                      |                       | 16           | DUS or CTA or MRA or DSA  | Yes, three mo unspecified | No                          |
| Dunbar (1965) <sup>1</sup>       | Retrospective |                      |                       | 13           | DSA                       | Yes, three mo unspecified | No                          |
| Evans (1974) <sup>22</sup>       | Retrospective |                      |                       | 44           | Unspecified               | Yes, three mo unspecified | No                          |
| Fernstrum (2020) <sup>34</sup>   | Retrospective | 30                   | 2                     | 27           | DUS and CTA               | Unspecified               | No                          |
| Geelkerken (2005) <sup>17</sup>  | Retrospective | 228                  | 3                     | 10           | DSA                       | Yes                       | No                          |
| Grus (2018) <sup>60</sup>        | Prospective   | 77                   |                       | 8            | CTA                       | Yes                       | No                          |
| Ho (2017) <sup>16</sup>          | Retrospective | Median 25 (6–72)     | 11                    | 43           | DUS or CTA or MRA or DSA  | Yes                       | No                          |
| Kafadar (2021) <sup>45</sup>     | Retrospective | 6                    |                       | 10           | CTA                       | Yes                       | No                          |
| Khrucharoen (2020) <sup>32</sup> | Retrospective | Median 16 (1–33)     |                       | 41           | DUS or CTA or MRA or DSA  | Yes, three mo unspecified | No                          |
| Kohn (2011) <sup>25</sup>        | Retrospective | 49                   |                       | 6            | Unspecified               | Y, three mo unspecified   | No                          |
| Marable (1968) <sup>20</sup>     | Retrospective |                      | 2                     | 19           | DSA                       | Yes                       | No                          |
| Mihas (1977) <sup>49</sup>       | Retrospective |                      |                       | 4            | DSA                       | Yes                       | No                          |
| Nguyen (2012) <sup>61</sup>      | Retrospective | Median 15 (2–23)     |                       | 5            | DUS and CTA               | Yes                       | No                          |
| Pather (2021) <sup>41</sup>      | Retrospective | 96 (48–144)          | 54                    | 100          | DUS or CTA or MRA         | Yes                       | No                          |
| Reddy (2019) <sup>50</sup>       | Retrospective | 15                   |                       | 3            | DUS                       | Yes                       | No                          |
| Reilly (1985) <sup>26</sup>      | Retrospective | 108                  | 7                     | 51           | DSA                       | Yes, three mo unspecified | No                          |
| Rogers (1982) <sup>19</sup>      | Retrospective | 58                   | 1                     | 7            | DSA                       | Yes, three mo unspecified | No                          |
| Roseborough (2009) <sup>46</sup> | Retrospective | Median 44            |                       | 15           | CTA or DSA                | Yes                       | No                          |
| Sahm (2020) <sup>47</sup>        | Prospective   | 5                    | 9                     | 18           | DUS and CTA or MRA or DSA | Yes                       | No                          |
| Skelly (2018) <sup>11</sup>      | Prospective   | 18                   | 44                    | 95           | DUS and CTA or MRA or DSA | Yes, three mo unspecified | Yes                         |
| Sultan (2013) <sup>27</sup>      | Retrospective | 60                   |                       | 11           | DUS and CTA               | Yes, three mo unspecified | No                          |
| Takach (1996) <sup>30</sup>      | Retrospective | 44                   |                       | 7            | DSA                       | Yes, three mo unspecified | No                          |
| Terpstra (1966) <sup>18</sup>    | Retrospective | Median 12            |                       | 5            | DSA                       | Yes                       | No                          |
| Thoolen (2015) <sup>14</sup>     | Retrospective | Median 6             | 1                     | 9            | DUS and CTA or MRA        | Yes, three mo unspecified | Yes                         |
| Tulloch (2010) <sup>48</sup>     | Retrospective | 14                   |                       | 14           | DUS or CTA or MRA or DSA  | Yes                       | No                          |

*Continued*

| Table 2-continued                 |                                     |                      |                       |              |                     |                           |                             |
|-----------------------------------|-------------------------------------|----------------------|-----------------------|--------------|---------------------|---------------------------|-----------------------------|
| Reference                         | Study design                        | Mean follow up – mo* | Lost to follow up – n | Patients – n | Imaging study       | Abdominal symptoms >3 mo* | Multidisciplinary diagnosis |
| van Petersen (2017) <sup>15</sup> | Retrospective                       | 6                    |                       | 129          | DUS and DSA         | Yes                       | Yes                         |
| Vaziri (2009) <sup>29</sup>       | Retrospective                       | 6                    |                       | 3            | DUS and CTA and MRA | Yes, three mo unspecified | No                          |
| Watson (1977) <sup>21</sup>       | Retrospective                       | Median 30 (14–33)    | 1                     | 19           | DSA                 | Yes                       | No                          |
| Weber (2016) <sup>6</sup>         | Retrospective                       |                      | 14                    | 39           | DUS                 | Yes, three mo unspecified | Yes                         |
| Total                             | Retrospective: 31<br>Prospective: 7 | Range 30–228         | 149                   | 880          |                     |                           | Yes: 6<br>No: 32            |

Data are presented as mean (95% confidence interval) or as median (interquartile range), unless stated otherwise. DUS = duplex ultrasound; CTA = computed tomography angiography; MRA = magnetic resonance angiography; DSA = digital subtraction angiography.

\* Indicates whether the time scale of the symptoms has or has not been specified, and, if so, whether the patients experienced abdominal symptoms for more than three months.

were retrieved for full text review. Thirty-eight papers including adults and six including paediatric patients met the inclusion criteria and were ultimately selected for the final critical appraisal (Fig. 1).

### Study design and diagnostic criteria

**Adult cohort.** The study design and diagnostic criteria of the 880 adult patients included are shown in Table 2.

The diagnosis of MALS was based on a consensus evaluation by a multidisciplinary team, as recommended in the international guidelines,<sup>2,3</sup> in only six of 38 adult studies.<sup>6,11–15</sup>

In nine studies, not all the reported adult patients ( $n = 280$ ) met the inclusion criteria for the current review. As the data were reported for each individual patient, the results of the 223 individuals that did meet the criteria were included in this systematic review.<sup>5,12,16–22</sup>

In 18 adult studies, it was not clearly described whether patients had abdominal symptoms for at least three months. However, the fact that these patients received a comprehensive and time consuming evaluation and work up makes it likely that symptoms were present for more than three months.<sup>1,6,11,13,14,19,22–33</sup> In one study, symptom relief after treatment suggested that patients were symptomatic, although it was not clearly stated that patients did have abdominal symptoms at the time of inclusion.<sup>34</sup> Based on these considerations, these studies were included in the review.

In one adult study, one of 21 patients was a 16 year old,<sup>23</sup> and in another study two of 39 patients were 17 years of age.<sup>6</sup> The data of these young people could not be separated from those of the adults. Because of the low number (three of 60 patients, 5%) and the fact that they were adolescents, both studies are included in the text and tables covering adult patients.

**Paediatric cohort.** The study design and diagnostic criteria of the six included studies describing 195 patients aged < 18 years are provided in Table 3.<sup>35–40</sup>

In two of six studies, a diagnosis of MALS was based on a consensus evaluation by a multidisciplinary team,<sup>38,40</sup> one

study did not describe the team members,<sup>38</sup> and in one study the team did not contain a radiologist,<sup>40</sup> as recommended in international guidelines.<sup>2,3</sup>

### Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2)

**Adult cohort.** The QUADAS-2 appraisal of the studies that included adult patients is shown in Supplementary Table S1. Of note, 35 of 38 (92%) of the studies scored a high or unclear risk of bias for the majority of the items. No studies had a low risk of bias for all items. The study by Thoolen *et al.* scored a low risk of bias in all but one item (the index test), because they did not clearly define threshold values for the outcomes.<sup>14</sup> The study by van Petersen *et al.* scored high on the index test risk of bias and applicability, because they solely reported symptom relief and no asymptomatic patients.<sup>15</sup> The study by Weber *et al.* scored high on patient selection risk of bias because 14 of 39 patients were lost to follow up (LTFU).<sup>6</sup> They also scored high on the index test risk of bias and applicability, because they solely reported symptom relief and no asymptomatic patients, and they did not clearly define threshold values for the outcomes.

**Paediatric cohort.** In the paediatric cohort, five of the six studies (83%) scored a high or unclear risk of bias for the majority of the items of the QUADAS-2 appraisal (Supplementary Table S2). The sixth study scored high on patient selection risk of bias because 28 patients were LTFU in the QoL assessment. They scored high on index test risk of bias and applicability, because they solely reported symptom relief and no asymptomatic patients, and they did not clearly define threshold values for the outcomes.<sup>38</sup>

### Patient demographics

**Adult cohort.** The demographics of the adult patients are reported in Table 4.

**Table 3. Study design and diagnostic criteria for 195 paediatric patients as reported in six studies for the treatment of median arcuate ligament syndrome**

| Reference                           | Study design                        | Follow up – mo | Lost to follow up – n | Patients – n | Imaging study                        | Abdominal symptoms >3 mo* | Multidisciplinary diagnosis |
|-------------------------------------|-------------------------------------|----------------|-----------------------|--------------|--------------------------------------|---------------------------|-----------------------------|
| Aschenbach (2011) <sup>35</sup>     | Retrospective                       |                | 0                     | 22           | MRA                                  | Yes, duration unknown     | No                          |
| Joyce (2014) <sup>36</sup>          | Prospective                         | 13 (2–24)      |                       | 6            | DUS and CTA or MRA                   | Yes                       | No <sup>†</sup>             |
| Klimas (2015) <sup>37</sup>         | Retrospective                       | Mean 62        |                       | 58           | DUS and CTA                          | Yes                       | No                          |
| Mak (2013) <sup>38</sup>            | Prospective                         | 9              | 28                    | 46           | DUS and CTA                          | Yes                       | Yes <sup>‡</sup>            |
| Moak (2021) <sup>39</sup>           | Prospective                         | 22 (7–37)      | 1                     | 31           | DUS and CTA (and DSA if discrepancy) | Yes, duration unknown     | No                          |
| Stiles-Shields (2018) <sup>40</sup> | Prospective                         | 6              |                       | 32           | DUS and CTA or MRA or DSA            | Unknown                   | Yes <sup>§</sup>            |
| Total                               | Prospective: 4<br>Retrospective : 2 | Range 6–62     | 29                    | 195          |                                      |                           | Yes: 2<br>No: 4             |

Data are presented as mean (95% confidence interval), unless stated otherwise. MRA = magnetic resonance angiography; DUS = duplex ultrasound; CTA = computed tomography angiography; DSA = digital subtraction angiography.

\* Indicates whether the time scale of the symptoms has or has not been specified, and, if so, if the patients experienced abdominal symptoms for more than three months.

<sup>†</sup> Consultation with vascular surgeon, paediatrician, and gastroenterologist but no team discussion

<sup>‡</sup> No description of team members of the multidisciplinary team.

<sup>§</sup> Multidisciplinary team without a radiologist.

CA release was performed in 851 adult patients (97%) and the remaining 29 (3%) underwent a bypass, percutaneous CA stenting procedure, plexus blockage, or other operation on the CA.

**Paediatric cohort.** The demographics of the paediatric patients are reported in Table 6.

All patients in the paediatric cohort underwent laparoscopic MAL release.

### Primary outcomes

**Adult cohort.** Symptom relief has been reported in Figure 2. Outcomes were not uniformly defined and reported. All studies reporting if patients were asymptomatic or experienced symptom relief after treatment were analysed. Some articles reported the number of patients who were asymptomatic after treatment, and some reported the number of patients who experienced a clear reduction of symptoms. These were reported separately (see Fig. 2). The forest plot was added to the table to provide a better insight into the data on a study level, without giving weight to one of the results. The error bars in the table represent the percentage of patients who experienced symptom relief, with the corresponding CIs. The percentages were calculated by dividing these by the number of patients in whom symptom relief was reported. Symptom relief was reported in 35 of the 38 adult studies describing 691 patients. In these 35 studies, 0% – 100% of the patients were free of symptoms and 75% – 100% reported a clear reduction of symptoms after surgical CA release. In 20 of 35 adult studies (57%), a symptom relief rate of > 70% was reported (range 71% – 100%; see Fig. 2).

Only one prospective adult study on plexus blockage met the inclusion criteria. This study showed symptom relief in 19 of 22 patients (86%).<sup>5</sup>

Five adult studies reported on QoL after treatment, as presented in Table 5. The prospective study by Skelly *et al.* was the only study to compare pre-operative with post-operative QoL, and revealed a statistically significant improvement in QoL from 68 to 80.3 ( $p < .001$ ) on a visual analogue scale (VAS; 0 – 100) six months post-operatively.<sup>11</sup> The prospective study by Berge *et al.* reported on QoL 12 months post-operatively only in patients who experienced symptom relief.<sup>13</sup> The VAS scores of these nine patients improved from 44 pre-operatively to 62 post-operatively. In the EQ-5D-5L, four of the five dimensions improved. The retrospective study by Ho *et al.* showed a numerical difference in the 12 item Short Form Health Survey (SF-12) between surgically and conservatively treated patients with MALS, with a median follow up of 24 months.<sup>16</sup> In comparing the outcomes of the physical and mental domains of the SF-12, the surgical group did better (–5 [95% CI –17 – 10] vs. –9 [95% CI –22 – 4] and 1 [95% CI –6 – 8] vs. –9 [95% CI –19 – 2], respectively). The retrospective study by Pather *et al.* showed a significantly higher mean Gastrointestinal Quality of Life Index (GIQLI) of 80 (95% CI 3 – 97) in patients in whom the symptoms had disappeared compared with 53 (95% CI 38 – 68) in patients with persisting symptoms up to eight years post-operatively for MALS ( $p < .001$ ).<sup>41</sup> The study by De'Ath *et al.* reported post-operative QoL scores only.<sup>31</sup>

**Paediatric cohort.** Symptom relief was reported in four of six studies ( $n = 156$ ; Fig. 2); 77% – 98% of patients were free of symptoms and 63% – 67% reported a clear reduction in symptoms after laparoscopic CA release. The study

**Table 4. Demographics of 880 adult patients as reported in 38 studies before treatment for median arcuate ligament syndrome**


| Reference                         | Female   | Mean age – y | Mean duration symptoms – mo | Mean BMI – kg/m <sup>2</sup> | Treatment  | Additional peri-operative procedure – n |
|-----------------------------------|----------|--------------|-----------------------------|------------------------------|--|---|
| Baccari (2009) <sup>42</sup>      | 11 (69)  | 54           | 12                          | 21                           | MALR   |   |
| Barbon (2021) <sup>5</sup>        |          |              |                             |                              | Plexus block   |   |
| Berard (2012) <sup>33</sup>       | 9 (82)   | Median 52    | Median 41                   | 20                           | MALR (n = 10),<br>bypass (n = 1)   | 1                                       |
| Berge (2020) <sup>13</sup>        | 8 (67)   | 46           |                             | 21                           | MALR   |   |
| Chaum (2021) <sup>28</sup>        | 4 (100)  | Median 30    |                             |                              | MALR   | 2                                       |
| Cienfuegos (2018) <sup>12</sup>   | 10 (91)  | Median 34    |                             | 21                           | MALR   |   |
| Coelho (2020) <sup>43</sup>       | 4 (67)   | 43           |                             |                              | MALR   |   |
| Columbo (2015) <sup>23</sup>      | 16 (76)  | Median 42    |                             | 20                           | MALR   |   |
| De'Ath (2018) <sup>31</sup>       | 5 (83)   | Median 30    |                             | Median 18                    | MALR   | 0                                       |
| Do (2013) <sup>24</sup>           | 10 (63)  |              | Median 16                   |                              | MALR   |   |
| Dunbar (1965) <sup>1</sup>        | 12 (92)  | 34.5         | Median 12                   |                              | MALR   |   |
| Evans (1974) <sup>22</sup>        |          |              |                             |                              | MALR   |   |
| Fernstrum (2020) <sup>34</sup>    | 18 (67)  | 49           | 57                          | 27                           | MALR   |   |
| Geelkerken (2005) <sup>17</sup>   |          | Median 47    | 24                          |                              | MALR   |   |
| Grus (2018) <sup>60</sup>         | 5 (63)   | 61           |                             | 21                           | MALR   | 8                                       |
| Ho (2017) <sup>16</sup>           | 33 (77)  | 36           |                             |                              | MALR   | 1                                       |
| Kafadar (2021) <sup>45</sup>      | 6 (60)   | 42           |                             |                              | MALR   |   |
| Khrucharoen (2020) <sup>32</sup>  | 37 (77)  | Median 41    |                             | Median 21                    | MALR   |   |
| Kohn (2011) <sup>25</sup>         | 3 (50)   | 38           |                             |                              | MALR   |   |
| Marable (1968) <sup>20</sup>      | 18 (95)  | Median 37    | Median 120                  |                              | MALR   |   |
| Mihás (1977) <sup>49</sup>        | 4 (100)  | 48           |                             |                              | Bypass (n = 2),<br>other (n = 2)*  |   |
| Nguyen (2012) <sup>61</sup>       |          | Median 29    | 26                          |                              | MALR   |   |
| Pather (2021) <sup>41</sup>       | 75 (75)  | 38           |                             | 23                           | MALR   | 25                                      |
| Reddy (2019) <sup>50</sup>        | 2 (67)   | 39           |                             |                              | MALR   |   |
| Reilly (1985) <sup>26</sup>       | 39 (76)  | 47           | Median 12                   |                              | MALR   | 18                                      |
| Rogers (1982) <sup>19</sup>       | 6 (86)   | 44           |                             |                              | MALR   |   |
| Roseborough (2009) <sup>46</sup>  | 13 (87)  | Median 41    |                             |                              | MALR   | 3                                       |
| Sahm (2020) <sup>47</sup>         | 9 (50)   | 39           | 34                          | 22                           | MALR (n = 16),<br>bypass (n = 3)   |   |
| Skelly (2018) <sup>11</sup>       | 41 (80)  | 31           | 69                          |                              | MALR   |   |
| Sultan (2013) <sup>27</sup>       | 10 (91)  | 50           |                             |                              | MALR   | 3                                       |
| Takach (1996) <sup>30</sup>       | 3 (43)   | 65           |                             |                              | MALR   | 5                                       |
| Terpstra (1966) <sup>18</sup>     | 4 (80)   | Median 48    |                             |                              | MALR   |   |
| Thoolen (2015) <sup>14</sup>      | 6 (67)   | 46           | Median 12                   | Median 22                    | MALR   |   |
| Tulloch (2010) <sup>48</sup>      | 12 (86)  | 45           |                             |                              | MALR   | 0                                       |
| van Petersen (2017) <sup>15</sup> | 106 (82) | 35           |                             |                              | MALR   |   |
| Vaziri (2009) <sup>29</sup>       | 3 (100)  | 44           |                             |                              | MALR   |   |
| Watson (1977) <sup>21</sup>       | 11 (58)  | Median 41    |                             |                              | MALR   |   |
| Weber (2016) <sup>6</sup>         | 33 (85)  | 41           |                             | 25                           | MALR   | 1                                       |
| Total                             | 568 (73) | Range 30–61  | Range 12–120                | Range 18–27                  | MALR (n = 851),<br>bypass (n = 3),<br>PTA (n = 2),<br>plexus block (n = 22),<br>other (n = 2)* | 67                                      |

Data are presented as n (%) or mean (95% confidence interval), unless stated otherwise. BMI = body mass index; MALR = median arcuate ligament release; PTA = percutaneous transluminal angioplasty.

\* Other operation on coeliac artery.

by Aschenbach *et al.*<sup>35</sup> reported the number of patients who were free of symptoms and the number of patients who experienced symptom relief after treatment (both results presented in Fig. 2). Only the number of patients who were free of symptoms (77%) was presented at the start of this section; presenting two sets of results for the same

patients in this range could be misleading. In the studies in which patients experienced symptom relief (last sentence of this section), only the number of patients who experienced symptom relief (100%) is presented. In two of four paediatric studies (50%), symptom relief of > 70% was reported (range 98% – 100%; see Fig. 2).



**Figure 2.** Symptom relief of patients among patients in whom the symptom relief was reported after treatment for median arcuate ligament syndrome as reported in a total of 43 studies. The error bars represent the percentage of patients who experienced symptomp relief with the corresponding confidence intervals.

Four paediatric studies reported an improvement in QoL after treatment (Table 6). The prospective study by Joyce *et al.* measured QoL via the Children Health Questionnaire – Parent Form 50 (CHQ-PF50), which reporting QoL according to seven domains reported by children and parents

three months post-operatively.<sup>36</sup> The children reported a significantly improved score in “Physical Functioning”, from 55 (20 – 90) to 96 (68 – 104) (P0.03); “Mental Health”, from 42 (16 – 68) to 69 (48 – 89) (P0.03); and in “Self Esteem”, from 47 (29 – 66) to 76 (60– 92) (P0.03). The



**Table 5.** Quality of life (QoL) of 880 adult patients after treatment for median arcuate ligament syndrome as reported in 38 studies

| Reference                         | QoL pre-operative or conservative                                | QoL post-operative                                  |
|-----------------------------------|--|---|
| Baccari (2009) <sup>42</sup>      |  |   |
| Barbon (2021) <sup>5</sup>        |  |   |
| Berard (2012) <sup>33</sup>       |  |   |
| Berge (2020) <sup>13</sup>        | VAS 44   | VAS 62  |
| Chaum (2021) <sup>28</sup>        |  |   |
| Cienfuegos (2018) <sup>12</sup>   |  |   |
| Coelho (2020) <sup>43</sup>       |  |   |
| Columbo (2015) <sup>23</sup>      |  |   |
| De'Ath (2018) <sup>31</sup>       |  | GLIQLI 129  |
| Do (2013) <sup>24</sup>           |  |   |
| Dunbar (1965) <sup>1</sup>        |  |   |
| Evans (1974) <sup>22</sup>        |  |   |
| Fernstrum (2020) <sup>34</sup>    |  |   |
| Geelkerken (2005) <sup>17</sup>   |  |   |
| Grus (2018) <sup>60</sup>         |  |   |
| Ho (2017) <sup>16</sup>           | Conservative SF-12:<br>Physical -9 (-22-4);<br>Mental -9 (-19-2) | SF-12:<br>Physical -4.9 (-17-7);<br>Mental 1 (-6-8) |
| Kafadar (2021) <sup>45</sup>      |  |   |
| Khrucharoen (2020) <sup>32</sup>  |  |   |
| Kohn (2011) <sup>25</sup>         |  |   |
| Marable (1968) <sup>20</sup>      |  |   |
| Mihás (1977) <sup>49</sup>        |  |   |
| Nguyen (2012) <sup>61</sup>       |  |   |
| Pather (2021) <sup>41</sup>       |  | GLIQLI 71 (51-91)                                   |
| Reddy (2019) <sup>50</sup>        |  |   |
| Reilly (1985) <sup>26</sup>       |  |   |
| Rogers (1982) <sup>19</sup>       |  |   |
| Roseborough (2009) <sup>46</sup>  |  |   |
| Sahm (2020) <sup>47</sup>         |  |   |
| Skelly (2018) <sup>11</sup>       | 68 (53-82)   | 80.3 (67-94)  |
| Sultan (2013) <sup>27</sup>       |  |   |
| Takach (1996) <sup>30</sup>       |  |   |
| Terpstra (1966) <sup>18</sup>     |  |   |
| Thoolen (2015) <sup>14</sup>      |  |   |
| Tulloch (2010) <sup>48</sup>      |  |   |
| van Petersen (2017) <sup>15</sup> |  |   |
| Vaziri (2009) <sup>29</sup>       |  |   |
| Watson (1977) <sup>21</sup>       |  |   |
| Weber (2016) <sup>6</sup>         |  |   |

Data are presented as mean (95% confidence interval).

VAS = visual analogue scale; SF-12 = 12 item Short Form Health Survey; GLIQLI = Gastrointestinal Quality of Life Index.

prospective study by Mak *et al.* reported a significantly improved Pediatric Quality of Life Inventory (PedsQL) from 58 to 77 ( $p < .001$ ) with a median follow up of 12 months.<sup>38</sup> The prospective study by Moak *et al.* reported self assessed QoL on a Likert scale from 1 to 10. QoL improved from 4.5 (2.4 - 6.6) to 5.3 (2.9 - 7.7; follow up QoL not described).<sup>39</sup> A prospective study by Stiles-Shields *et al.* reported a significantly improved PedsQL from 64 (47 - 80) to 74 (56 - 93;  $p = .004$ ) six months post-operatively.<sup>40</sup>

### Secondary outcomes

**Adult cohort.** A variety of secondary clinical outcome parameters have been reported in adult patients (Supplementary Table S3).

Twenty-one adult studies (including 512 patients) reported complications in 60 patients (12% of the patients); the most common was intra-operative bleeding in 24 patients (41% of the reported complications).<sup>6,11,12,14,16,21,24,27,29-32,34,41-48</sup>

The "in hospital" and "30 days post-operative" mortality rate was zero, as reported in 21 studies including 368 patients.<sup>5,6,18,19,21,23,24,27,29-33,41,43-46,48-50</sup> In the study by Rogers *et al.*, one patient died two months after MAL release; post mortem examination failed to reveal the cause of death.

The anatomical outcomes of surgical CA release in studies including adult patients are provided in Supplementary Table 5. The adequacy of the CA release was determined with Doppler ultrasound in eight studies by reporting peak systolic velocity (PSV) values before and after surgery.<sup>6,11,13,25,27,29,41,47</sup> Two studies published pre- and post-operative inspiratory and expiratory PSV data;<sup>41,47</sup> one

**Table 6. Demographics and quality of life (QoL) of 195 paediatric patients after laparoscopic median arcuate ligament release reported in six studies**

| Reference                           | Female * | Follow up – mo† | Age – y†    | Pre-operative QoL†  | Post-operative QoL†  |
|-------------------------------------|----------|-----------------|-------------|---|--|
| Aschenbach (2011) <sup>35</sup>     |          |                 | 15          |   |  |
| Joyce (2014) <sup>36</sup>          | 5 (83)   | 13 (2–24)       | 16 (14–17)  | CHQ-PF-50 Physical Functioning 55 (20–90), Emotional 44 (6–83), Behavioural 59 (10–108), Physical 26 (3–59), Bodily Pain 10 (–6–26), Mental Health 42 (16–68), Self-Esteem 47 (29–66), General Health Perceptions 17 (2–33) | CHQ-PF50 Physical Functioning 96 (68–104), Emotional 81 (49–113), Behavioural 83 (43–124), Physical 76 (37–115), Bodily Pain 57 (27–86), Mental Health 69 (48–89), Self-Esteem 76 (60–92), General Health Perceptions 48 (30–66) |
| Klimas (2015) <sup>37</sup>         | 47 (81)  | Mean 62         | 17          |   |  |
| Mak (2013) <sup>38</sup>            | 42 (91)  | 9               | 16 (16–17)  | PedsQL 58   | PedsQL 77  |
| Moak (2021) <sup>39</sup>           | 28 (90)  | 22 (7–37)       | 17 (15–19)  | Likert 4.5 (2.4–6.6)  | Likert 5.3 (2.9–7.7)   |
| Stiles-Shields (2018) <sup>40</sup> | 30 (94)  | 6               | 15 (14–17)  | PedsQL 64 (47–80)   | PedsQL 74 (56–93)  |
| Total                               | 152 (78) | Range 6–62      | Range 15–17 |   |  |

CHQ-PF50 = Child Health Questionnaire – Parent Form 50; PedsQL = Paediatric Quality of Life Inventory.

\* n (%).

† Displayed as mean (95% confidence interval), unless stated otherwise.

study only inspiratory values;<sup>11</sup> one study only expiratory values;<sup>29</sup> and in four studies it was not specified whether these were inspiratory or expiratory PSV data.<sup>6,13,25,27</sup> In nine studies including 274 patients, post-intervention CA patency was determined with duplex ultrasound, computed tomography angiography, or magnetic resonance angiography.<sup>6,15,26,28,33,42–45</sup> A patent CA was established in 212 patients (77%).

**Paediatric cohort.** A variety of secondary clinical outcome parameters have been reported in paediatric patients (Supplementary Table S4). Because of the low patient numbers in which secondary outcomes have been reported, these will not be discussed further.

The anatomical outcomes of laparoscopic CA release in paediatric patients are shown in Supplementary Table S6). Doppler ultrasound was performed, and pre-operative and post-operative PSV values were reported in all six studies.

## DISCUSSION

This systematic review, which included 38 studies describing the outcomes of 880 adult patients and six describing the outcomes of 195 paediatric patients, suggests a sustainable symptom relief above 70% in the majority of adults from three months up to 228 months after treatment for MALS and in half of the paediatric studies from six months up to 62 months after laparoscopic MAL release. Two adult studies compared QoL before and after surgical treatment for MALS and both showed an improved QoL after treatment. Four paediatric studies compared QoL before and after laparoscopic MAL release, and these also showed improved QoL

after treatment. CA release was performed safely, with a very low complication rate and nearly zero probability of death.

Only one study, including 22 adult patients, reported symptom relief of 88% after coeliac plexus blockage.<sup>5</sup>

None of the articles included in the present review was of sufficient quality to meet the criteria for a “low risk” score, according to the QUADAS-2 tool. Most importantly, in the majority of studies, outcome parameters were ill defined and not uniformly defined and or presented, with a risk of confounding and selection bias. The consequence is that the results must be interpreted with caution.

When starting this review, the idea was to perform a systematic review with comparative meta-analysis of the data. The outcome of the previous reviews allowed for both a systematic and a scoping review approach. A systematic review design was chosen in line with the recommendation in the most recent guideline describing diagnostic criteria.<sup>3</sup> Based on the design of the included articles (solely observational studies and case series), the “quality of evidence” of all studies would be “low” or “very low”.<sup>51</sup> Owing to the heterogeneity of the inclusion and outcome criteria, it was decided to perform solely a narrative description of the results without a formal meta-analysis, which would provide the readers with misleading data that should not be (mis)used in future reports. The justified criticism of performing a systematic review in a rare disease is the risk of selection and publication bias. After exploring the data, the actual quality of evidence appeared to be very low due to the observational study designs, inherent patient selection, and variable outcome parameters. Without data synthesis, a GRADE (Grading of Recommendations, Assessment, Development and Evaluations) evaluation could

not be completed. To answer the research question, both guidelines committees recommended to perform a randomised controlled trial.<sup>2,3</sup>

The reported symptom relief above 70%, as presented in the majority of the studies, is substantially higher than the placebo response of 18% – 57% described in five sham operation studies.<sup>52–56</sup> Jimenez *et al.* presented an 85% immediate symptom improvement of 400 patients with MALS after laparoscopic and open CA release with a late recurrence in 19 patients in the open group (6.8%) and seven patients in the laparoscopic group (5.7%).<sup>7</sup> Owing to the above arguments, it is inappropriate to present aggregated data on these studies. After Jimenez *et al.*, Goodall *et al.* carried out a literature overview in 2020, which was presented as a description of some of the literature on MALS without a methodology or the design of a systematic review.<sup>8</sup> The current review included 44 studies of adult and paediatric patients (1 096 patients in total), 17 of which (266 patients) were also included in the study by Jimenez together with 27 new studies (830 patients). The second difference between the present work and the previous studies is that the articles included in the current research had a longer follow up period of three months up to 228 months, compared with the articles included by Jimenez *et al.* A third difference is that the current review applied more stringent selection criteria. This systematic review only included studies if patients had external compression of the CA by the MAL on imaging studies plus abdominal symptoms (for more than three months), whereas Jimenez *et al.* included all studies that presented outcomes after surgical treatment for MALS.<sup>7</sup>

A limitation of this review is that the aim was to only include patients with abdominal symptoms, but some articles were included based on the fact that it was very likely that they experienced abdominal symptoms for at least three months.<sup>1,6,11,13,14,19,22–34</sup>

This systematic review included a separate description of paediatric studies showing sustainable symptom relief rate of 63% – 98% after laparoscopic MAL release. The present review underlined that MALS in patients younger than 12 years of age is rare, supporting the hypothesis that compression of the CA arises during puberty as the thorax/abdominal ratio increases.

Two prospective cohort studies provided evidence that patients with MALS have ischaemia of the gastric mucosa and showed improvement of validated mesenteric mucosal perfusion tests after successful CA release.<sup>13,57</sup> Moreover, in a study of 129 patients, 91 (71%) experienced relief of symptoms, irrespective of the fact that the coeliac plexus had been left untouched during surgery.<sup>15</sup> This does not necessarily mean that the ischaemia is the cause of the pain, nor that neurogenic mechanisms are also involved. The present systematic review undermines the half century old statement of Szilagyi *et al.*<sup>4</sup> that “no patient had ever been proven, on scientific grounds, to have an abnormality of intestinal structure or function which was caused by extraluminal compression of the coeliac artery, or supposed relief from the operation could be anything other than a placebo effect”. The present review supports both guideline committees,

acknowledging not only that MALS exists as disease entity, but also that studies of sufficient scientific quality are lacking to recommend specific treatments.<sup>2,3</sup> To facilitate the development of evidence based guidelines for the management of MALS, both guideline committees recommend a blinded RCT comparing CA release with a sham operation. A systemic review reconsidering the ethics of sham interventions concluded that sham interventions are acceptable, provided the pre-conditions of scientific necessity, reasonable risks, and valid informed consent are fulfilled.<sup>58</sup> The suggestion of a randomised placebo controlled patient and observer blinded clinical superiority trial in patients suspected of MALS will give the irrefutable answer needed by patients and clinicians. Included patients should have a multidisciplinary consensus diagnosis based on symptoms fitting CMI, combined with appropriate imaging studies,<sup>59</sup> and should be treated by either surgical CA release or a sham operation. Besides analysing anatomical and clinical success, the outcome parameters should represent QoL, psychiatric disorders, and the societal burden of disease. If these criteria are met, the Szilagyi debate may finally be settled, and it will either underline the usefulness of surgical CA release as a (cost) effective treatment for MALS or it will prevent patients with disabling abdominal complaints from undergoing an ineffective intervention.

In conclusion, this systematic review suggests a sustainable symptom relief above 70% after treatment for MALS in the majority of the adult and paediatric studies, but, owing to the heterogeneity of the inclusion criteria and outcome parameters, the risk of bias is high and a formal meta-analysis could not be performed.

## CONFLICT OF INTEREST STATEMENT AND FUNDING

None.

## APPENDIX A. SUPPLEMENTARY DATA

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ejvs.2022.08.033>.

## REFERENCES

- Dunbar DJ, Molnar W, Beman FF, Marable SA. Compression of the celiac trunk and abdominal angina. *Am J Roentgenol* 1965;95:731–44.
- Björck M, Koelmay M, Acosta S, Bastos Goncalves F, Kölbel T, Kolkman JJ, et al. Editor's Choice – Management of the diseases of mesenteric arteries and veins. *Eur J Vasc Endovasc Surg* 2017;53:460–510.
- Terlouw LG, Moelker A, Abrahamsen J, Acosta S, Bakker OJ, Baumgartner I, et al. European guidelines on chronic mesenteric ischaemia – joint United European Gastroenterology, European Association for Gastroenterology, Endoscopy and Nutrition, European Society of Gastrointestinal and Abdominal Radiology, Netherlands Association of Hepa. *United Eur Gastroenterol J* 2020;8:371–95.
- Szilagyi DE, Rian RL, Elliott JP, Smith RF. The celiac artery compression syndrome: does it exist? *Surgery* 1972;72:849–63.
- Barbon DA, Hsu R, Noga J, Lazzara B, Miller T, Stainken BF. Clinical response to celiac plexus block confirms the neurogenic etiology of median arcuate ligament syndrome. *J Vasc Interv Radiol* 2021;32:1081–7.

- 6 Weber JM, Boules M, Fong K, Abraham B, Bena J, El-Hayek K, et al. Median arcuate ligament syndrome is not a vascular disease. *Ann Vasc Surg* 2016;**30**:22–7.
- 7 Jimenez JC, Harlander-Locke M, Dutson EP. Open and laparoscopic treatment of median arcuate ligament syndrome. *J Vasc Surg* 2012;**56**:869–73.
- 8 Goodall R, Langridge B, Onida S, Ellis M, Lane T, Davies AH. Median arcuate ligament syndrome. *J Vasc Surg* 2020;**71**:2170–6.
- 9 Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;**372**:n71.
- 10 Whiting PF. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med* 2011;**155**:529.
- 11 Skelly CL, Stiles-Shields C, Mak GZ, Speaker CR, Lorenz J, Anitescu M, et al. The impact of psychiatric comorbidities on patient-reported surgical outcomes in adults treated for the median arcuate ligament syndrome. *J Vasc Surg* 2018;**68**:1414–21.
- 12 Cienfuegos JA, Estevez MG, Ruiz-Canela M, Pardo F, Diez-Caballero A, Vivas I, et al. Laparoscopic treatment of median arcuate ligament syndrome: analysis of long-term outcomes and predictive factors. *J Gastrointest Surg* 2018;**22**:713–21.
- 13 Berge ST, Safi N, Medhus AW, Sundhagen JO, Hisdal J, Kazmi SS. Perioperative microcirculatory changes detected with gastroscopy assisted laser Doppler flowmetry and visible light spectroscopy in patients with median arcuate ligament syndrome. *Vasc Health Risk Manag* 2020;**16**:331–41.
- 14 Thoolen SJJ, van der Vliet WJ, Kent TS, Callery MP, Dib MJ, Hamdan A, et al. Technique and outcomes of robot-assisted median arcuate ligament release for celiac artery compression syndrome. *J Vasc Surg* 2015;**61**:1278–84.
- 15 van Petersen AS, Kolkman JJ, Gerrits DG, van der Palen J, Zeebregts CJ, Geelkerken RH, et al. Clinical significance of mesenteric arterial collateral circulation in patients with celiac artery compression syndrome. *J Vasc Surg* 2017;**65**:1366–74.
- 16 Ho KKF, Walker P, Smithers BM, Foster W, Nathanson L, O'Rourke N, et al. Outcome predictors in median arcuate ligament syndrome. *J Vasc Surg* 2017;**65**:1745–52.
- 17 Geelkerken RH, van Bockel JH, De Roos WK, Hermans J. Coeliac artery compression syndrome: the effect of decompression. *Br J Surg* 2005;**77**:807–9.
- 18 Terpstra JL. Intestinal angina secondary to compression of the coeliac axis. *Arch Chir Neerl* 1966;**18**:245–53.
- 19 Rogers DM, Thompson JE, Garrett WV, Talkington CM, Patman RD. Mesenteric vascular problems. *Ann Surg* 1982;**195**:554–65.
- 20 Marable SA, Kaplan MF, Beman FM, Molnar W. Celiac compression syndrome. *Am J Surg* 1968;**115**:97–102.
- 21 Watson WC. Celiac axis compression. *Ann Intern Med* 1977;**86**:278.
- 22 Evans WE. Long-term evaluation of the celiac band syndrome. *Surgery* 1974;**76**:867–71.
- 23 Columbo JA, Trus T, Nolan B, Goodney P, Rzuclidlo E, Powell R, et al. Contemporary management of median arcuate ligament syndrome provides early symptom improvement. *J Vasc Surg* 2015;**62**:151–6.
- 24 Do MV, Smith TA, Bazan HA, Sternbergh WC, Abbas AE, Richardson WS. Laparoscopic versus robot-assisted surgery for median arcuate ligament syndrome. *Surg Endosc* 2013;**27**:4060–6.
- 25 Kohn GP, Bitar RS, Farber MA, Marston WA, Overby DW, Farrell TM. Treatment options and outcomes for celiac artery compression syndrome. *Surg Innov* 2011;**18**:338–43.
- 26 Reilly LM, Ammar A, Stoney R, Ehrenfeld W. Late results following operative repair for celiac artery compression syndrome. *J Vasc Surg* 1985;**2**:79–91.
- 27 Sultan S, Hynes N, Elsafty N, Tawfick W. Eight years experience in the management of median arcuate ligament syndrome by decompression, celiac ganglion sympathectomy, and selective revascularization. *Vasc Endovascular Surg* 2013;**47**:614–9.
- 28 Chaum M, Shouhed D, Kim S, Walts AE, Marchevsky AM. Clinicopathologic findings in patients with median arcuate ligament syndrome (celiac artery compression syndrome). *Ann Diagn Pathol* 2021;**52**:151732.
- 29 Vaziri K, Hungness ES, Pearson EG, Soper NJ. Laparoscopic treatment of celiac artery compression syndrome: case series and review of current treatment modalities. *J Gastrointest Surg* 2009;**13**:293–8.
- 30 Takach TJ, Livesay JJ, Reul GJ, Cooley DA. Celiac compression syndrome: tailored therapy based on intraoperative findings. *J Am Coll Surg* 1996;**183**:606–10.
- 31 De'Ath HD, Wong S, Szentpali K, Somers S, Peck T, Wakefield CH. The laparoscopic management of median arcuate ligament syndrome and its long-term outcomes. *J Laparoendosc Adv Surg Tech* 2018;**28**:1359–63.
- 32 Khrucharoen U, Juo Y-Y, Sanaiha Y, Finn JP, Jimenez JC, Dutson EP. Factors associated with symptomology of celiac artery compression and outcomes following median arcuate ligament release. *Ann Vasc Surg* 2020;**62**:248–57.
- 33 Berard X, Cau J, Déglise S, Trombert D, Saint-Lebes B, Midy D, et al. Laparoscopic surgery for coeliac artery compression syndrome: current management and technical aspects. *Eur J Vasc Endovasc Surg* 2012;**43**:38–42.
- 34 Fernstrum C, Pryor M, Wright GP, Wolf AM. Robotic surgery for median arcuate ligament syndrome. *JSLs J Soc Laparosc Robot Surg* 2020;**24**:e2020.00014.
- 35 Aschenbach R, Basche S, Vogl TJ. Compression of the celiac trunk caused by median arcuate ligament in children and adolescent subjects: evaluation with contrast-enhanced MR angiography and comparison with Doppler US evaluation. *J Vasc Interv Radiol* 2011;**22**:556–61.
- 36 Joyce DD, Antiel RM, Oderich G, Gloviczki P, Tung J, Grothe R, et al. Pediatric median arcuate ligament syndrome: surgical outcomes and quality of life. *J Laparoendosc Adv Surg Tech* 2014;**24**:104–10.
- 37 Klimas A, Lemmer A, Bergert H, Brodhun M, Scholbach T, Großer K. Laparoscopic treatment of celiac artery compression syndrome in children and adolescents. *Vasa* 2015;**44**:305–12.
- 38 Mak GZ, Speaker C, Anderson K, Stiles-Shields C, Lorenz J, Drossos T, et al. Median arcuate ligament syndrome in the pediatric population. *J Pediatr Surg* 2013;**48**:2261–70.
- 39 Moak JP, Ramwell C, Fabian R, Hanumanthaiah S, Darbari A, Kane TD. Median arcuate ligament syndrome with orthostatic intolerance: intermediate-term outcomes following surgical intervention. *J Pediatr* 2021;**231**:141–7.
- 40 Stiles-Shields C, CL S, GZ M, Speaker C, Boyd H, O'Brien S, et al. Psychological factors and outcomes in the surgical treatment of pediatric patients with median arcuate ligament syndrome. *J Pediatr Gastroenterol Nutr* 2018;**66**:866–71.
- 41 Pather K, Kärkkäinen JM, Tenorio ER, Bower TC, Kalra M, DeMartino R, et al. Long-term symptom improvement and health-related quality of life after operative management of median arcuate ligament syndrome. *J Vasc Surg* 2021;**73**:2050–8.
- 42 Baccari P, Civilini E, Dordoni L, Melissano G, Nicoletti R, Chiesa R. Celiac artery compression syndrome managed by laparoscopy. *J Vasc Surg* 2009;**50**:134–9.
- 43 Coelho JCU, Hosni AV El, Claus CM, Aguilera YSH, Abot GP, de Freitas ATC, et al. Treatment of median arcuate ligament syndrome: outcome of laparoscopic approach. *ABCD Arq Bras Cir Dig (São Paulo)* 2020;**33**:295–6.
- 44 Grus T, Lambert L, Vidim T, Grusova G, Klika T. Intraoperative measurement of pressure gradient in median arcuate ligament syndrome as a rationale for radical surgical approach. *Acta Chir Belg* 2018;**118**:36–41.
- 45 Kafadar M, Oguz A, Aday U, Bilge H, Ö Basol. Median arcuate ligament (Dunbar) syndrome: laparoscopic management and clinical outcomes of a single centre. *J Minim Access Surg* 2021;**17**:363–8.
- 46 Roseborough GS. Laparoscopic management of celiac artery compression syndrome. *J Vasc Surg* 2009;**50**:124–33.
- 47 Sahm M, Otto R, Pross M, Scholbach T, Mantke R. Laparoscopic therapy of the coeliac artery compression syndrome: a critical

- analysis of the current standard procedure. *Ann R Coll Surg Engl* 2020;**102**:104–9.
- 48 Tulloch AW, Jimenez JC, Lawrence PF, Dutson EP, Moore WS, Rigberg DA, et al. Laparoscopic versus open celiac ganglionectomy in patients with median arcuate ligament syndrome. *J Vasc Surg* 2010;**52**:1283–9.
- 49 Mihas AA, Laws HL, Jander HP. Surgical treatment of the celiac axis compression syndrome. *Am J Surg* 1977;**133**:688–91.
- 50 Reddy EV, Shroff G, Reddy VB, Somayajulu AVP. Laparoscopic management of median arcuate ligament syndrome: single center experience. *World J Laparosc Surg* 2019;**12**:39–42.
- 51 Schünemann H, Brożek J, Guyatt G, Oxman A. GRADE handbook for grading quality of evidence and strength of recommendations. Available at: <https://gdt.gradepro.org/app/handbook/handbook.html> [Accessed 9 September 2022].
- 52 Swank D, Swank-Bordewijk S, Hop W, van Erp W, Janssen I, Bonjer H, et al. Laparoscopic adhesiolysis in patients with chronic abdominal pain: a blinded randomised controlled multi-centre trial. *Lancet* 2003;**361**:1247–51.
- 53 Boelens OB, van Assen T, Houterman S, Scheltinga MR, Roumen RM. A double-blind, randomized, controlled trial on surgery for chronic abdominal pain due to anterior cutaneous nerve entrapment syndrome. *Ann Surg* 2013;**257**:845–9.
- 54 Roumen RMH, Groenendijk RPR, Sloots CEJ, Duthoi KES, Scheltinga MRM, Bruijninx CMA. Randomized clinical trial evaluating elective laparoscopic appendicectomy for chronic right lower-quadrant pain. *Br J Surg* 2008;**95**:169–74.
- 55 Guyuron B, Reed D, Kriegler JS, Davis J, Pashmini N, Amini S. A placebo-controlled surgical trial of the treatment of migraine headaches. *Plast Reconstr Surg* 2009;**124**:461–8.
- 56 Abbot J, Hawe J, Hunter D, Holmes M, Finn P, Garry R. Laparoscopic excision of endometriosis: a randomized, placebo-controlled trial. *Fertil Steril* 2004;**82**:878–84.
- 57 Mensink PBF, van Petersen AS, Kolkman JJ, Otte JA, Huisman AB, Geelkerken RH. Gastric exercise tonometry: the key investigation in patients with suspected celiac artery compression syndrome. *J Vasc Surg* 2006;**44**:277–81.
- 58 Niemansburg SL, van Delden JJM, Dhert WJA, Bredenoord AL. Reconsidering the ethics of sham interventions in an era of emerging technologies. *Surgery* 2015;**157**:801–10.
- 59 Dijk LJ, Noord D, Vries AC, Kolkman JJ, Geelkerken RH, Verhagen HJM, et al. Clinical management of chronic mesenteric ischemia. *United Eur Gastroenterol J* 2019;**7**:179–88.
- 60 Grus T, Klika T, Grusová G, Lindner J, Lambert L. Dunbar syndrome – single-center experience with surgical treatment. *Rozhl Chir* 2018;**97**:514–7.
- 61 Nguyen T, Neale M, Lane R, Schiavone V, Samra JS, Hugh TJ. Laparoscopic management of the median arcuate ligament syndrome. *ANZ J Surg* 2012;**82**:265–8.